Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab Achieves $3M Janssen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Genmab Achieves $3M Janssen Milestone

Advances DuoBody candidate targeting cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has reached a milestone in its collaboration with Janssen Biotech, triggering a $3 million milestone payment for preclinical progress with a DuoBody product candidate targeting cancer.
To date, Janssen has optioned 11 programs out of 20 under the bispecific DuoBody platform collaboration with Genmab. Genmab currently has five commercial partnerships for its DuoBody technology.

“This milestone is another step in the continued validation of our DuoBody technology. Our technology collaborations are a key part of Genmab’s strategy to generate diverse revenue streams and we are very pleased with the continued rapid progress of the DuoBody programs in our collaboration with Janssen,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Under the original July 2012 agreement, Janssen has the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 against multiple disease targets. Genmab received $3.5 million upfront and is entitled to milestone and license payments of as much as $175 million, as well as royalties.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics